Viridian Therapeutics Q2 net loss widens as Lumvoa launch lifts costs

Viridian Therapeutics

06/08/2026 12:36

Overview
U.S. biotech firm's Q2 net loss widened yr/yr as Lumvoa launch drove higher SG&A costs
Company ended Q2 with $981.5 mln in cash

Result Drivers
LUMVOA LAUNCH - Co said Lumvoa launch drove higher SG&A expenses and strong early physician engagement
R&D EXPENSES - Co said Q2 R&D expenses fell due to reduced costs for veligrotug and elegrobart studies, partly offset by investment in TSHR program and higher personnel costs

Company press release: ID:nBwc5rCwya

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$127.12 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Viridian Therapeutics Inc is $35.00, about 66.1% above its August 5 closing price of $21.07

Reuters Recommended Reads
Aug 3 - Ocular Therapeutix Q2 product revenue flat, net loss widens on higher spending
Aug 5 - Biopharma firm MannKind Q2 posts net loss on product launch expenses
Aug 4 - Dianthus Therapeutics Q2 net loss widens as R&D costs rise

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)